Subsequent Event (Details) - FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, EVOMELA, and KHAPZORY [Member] - Acrotech Biopharma LLC [Member] - Subsequent Event [Member] $ in Millions	Jan. 17, 2019 USD ($) employee
Subsequent Event [Line Items]
Upfront payment expected to be received	$ 160
Consideration held in escrow for six months	$ 4
Period consideration is held in escrow	6 months
Payment receivable on achievement of regulatory milestones	$ 140
Reduction in employees, number of employees | employee	90
Maximum [Member]
Subsequent Event [Line Items]
Upfront payment expected to be received	$ 300